ROS1
ROS1 fusion positive NSCLC consists of 1-2% of patients with NSCLC. Several methods exist for detection of ROS1 rearrangements including next generation sequencing (NGS), Fluorescence in situ hybridization (FISH), Immuno histochemistry (IHC), and reverse transcription–polymerase chain reaction (RT-PCR).
NGS has advantages over other methodologies including simultaneous evaluation of multiple oncogenic drivers.
As of February 2022, there are two FDA-approved targeted therapy agents for ROS1 fusion positive NSCLC: Crizotinib and Entrectinib.
Drugs
References
Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019 Jul 1;30(7):1121-1126. doi: 10.1093/annonc/mdz131. PMID: 30980071
Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1. PMID: 33646820.